157 related articles for article (PubMed ID: 12017297)
1. In vitro activity of glufosfamide in childhood acute leukemia.
Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report.
Styczyński J; Wysocki M; Debski R; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):221-5. PubMed ID: 12136944
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
4. Induction of DNA breakage in U937 cells by oxazaphosphorines.
Mazur L; Opydo-Chanek M; Stojak M; Baran J; Niemeyer U
Folia Biol (Krakow); 2010; 58(1-2):15-20. PubMed ID: 20420190
[TBL] [Abstract][Full Text] [Related]
5. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
6. [Perfect drug targeting. Glufosfamide a new derivative].
Holzgrabe U
Pharm Unserer Zeit; 2006; 35(2):158-9. PubMed ID: 16583570
[No Abstract] [Full Text] [Related]
7. Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: preliminary report.
Styczyński J; Wysocki M; Debski R; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):93-8. PubMed ID: 12136961
[TBL] [Abstract][Full Text] [Related]
8. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
[TBL] [Abstract][Full Text] [Related]
10. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.
Pieters R; Loonen AH; Huismans DR; Broekema GJ; Dirven MW; Heyenbrok MW; Hählen K; Veerman AJ
Blood; 1990 Dec; 76(11):2327-36. PubMed ID: 2257305
[TBL] [Abstract][Full Text] [Related]
12. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
[TBL] [Abstract][Full Text] [Related]
13. Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
Jun KR; Jang S; Chi HS; Lee KH; Lee JH; Choi SJ; Seo JJ; Moon HN; Im HJ; Park CJ
Korean J Lab Med; 2007 Apr; 27(2):89-95. PubMed ID: 18094557
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo activity of thalidomide in childhood acute leukemia.
Styczynski J; Czyzewski K; Wysocki M
Leuk Lymphoma; 2006 Jun; 47(6):1123-8. PubMed ID: 16840205
[TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia.
Styczyński J; Wysocki M; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk A; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Neoplasma; 2002; 49(3):178-83. PubMed ID: 12098004
[TBL] [Abstract][Full Text] [Related]
17. Glufosfamide: beta-D-Glc-IPM, D 19575.
Drugs R D; 2005; 6(1):49-52. PubMed ID: 15801867
[TBL] [Abstract][Full Text] [Related]
18. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.
Ammons WS; Wang JW; Yang Z; Tidmarsh GF; Hoffman RM
Neoplasia; 2007 Aug; 9(8):625-33. PubMed ID: 17786181
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of new generation oxazaphosphorines on human promyelocytic leukemia cells.
Mazur L; Opydo-Chanek M; Stojak M; Niemeyer U
Folia Biol (Krakow); 2013; 61(1-2):31-40. PubMed ID: 23767290
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Briasoulis E; Judson I; Pavlidis N; Beale P; Wanders J; Groot Y; Veerman G; Schuessler M; Niebch G; Siamopoulos K; Tzamakou E; Rammou D; Wolf L; Walker R; Hanauske A
J Clin Oncol; 2000 Oct; 18(20):3535-44. PubMed ID: 11032596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
